Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation.
Julia ManassonDavid S WallachGiuliana GugginoMatthew StapyltonMichelle H BadriGary SolomonSoumya M ReddyRoxana CorasAlexander A AksenovDrew R JonesParvathy V GirijaAndrea L NeimannAdriana HeguyLeopoldo N SegalPieter C DorresteinRichard BonneauMónica GumaFrancesco CicciaCarles UbedaJose C ClementeJose U ScherPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
In a subgroup of SpA patients, the initiation of IL-17A blockade correlated with features of subclinical gut inflammation and intestinal dysbiosis of certain bacterial and fungal taxa, most notably C albicans. Further, IL-17i-related CD was associated with overexpression of IL-25/IL-17E-producing tuft cells and ILC2s. These results may help to explain the potential link between inhibition of a specific IL-17 pathway and the (sub)clinical gut inflammation observed in SpA.
Keyphrases
- oxidative stress
- end stage renal disease
- newly diagnosed
- ejection fraction
- cell proliferation
- chronic kidney disease
- prognostic factors
- ankylosing spondylitis
- candida albicans
- climate change
- cell cycle arrest
- risk assessment
- rheumatoid arthritis
- patient reported outcomes
- open label
- pi k akt
- nk cells
- study protocol
- patient reported